株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非小細胞肺がん:KOLの考察

Non-Small Cell Lung Cancer: KOL Insight

発行 FirstWord 商品コード 336411
出版日 ページ情報 英文 209 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
非小細胞肺がん:KOLの考察 Non-Small Cell Lung Cancer: KOL Insight
出版日: 2015年07月01日 ページ情報: 英文 209 Pages
概要

非小細胞肺がん (NSCLC) の治療アルゴリズムは急速に発展しており、ますます複雑化・細分化しています。

当レポートでは、非小細胞肺がん (NSCLC) の市場およびパイプラインについて、確立した治療法・新しい治療法に重点を置きつつ調査しており、主要KOL12人へのインタビューとともに、お届け致します。

主な調査内容

  • NSCLCの治療アルゴリズムを破壊・再形成する可能性がある新薬は?
  • 将来のNSCLC治療に大きな影響を及ぼす可能性のある臨床試験は?
  • 現在の標的療法・免疫療法の利用はどのように発展するか、または発展する可能性があるか?
  • 新治療薬・将来の治療薬に関する専門家の大きな関心事は?
  • バイオマーカー・患者区分は将来のNSCLC治療へどのような影響を及ぼすか?

調査対象の現在の治療薬

  • 免疫療法
    • Opdivo (nivolumab; Bristol-Myers Squibb)
  • EGFR変異陽性NSCLC
    • Tarceva (erlotinib; Astellas/Roche)
    • Iressa (gefitinib; AstraZeneca)
    • Gilotrif/Giotrif (afatinib; Boehringer Ingelheim)
  • ALK陽性NSCLC
    • Zykadia (ceritinib; Novartis)
  • ALK・EGFR変異陰性NSCLC
    • Avastin (bevacizumab; Roche)
    • Vargatef (nintedanib; Boehringer Ingelheim)
    • Cyramza (ramucirumab; Eli Lilly)

調査対象の将来の治療薬

  • 免疫療法
    • Keytruda (pembrolizumab; Merck & Co.)
    • Atezolizumab (MPDL3280A; Roche)
    • Durvalumab (MEDI4736; AstraZeneca)
    • Yervoy (ipilimumab; BMS)
  • EGFR変異陽性NSCLC
    • Mereletinib (AZD9291; AstraZeneca)
    • Rociletinib (CO-1686; Celgene/Clovis Oncology)
    • Dacomitinib (PF-00299804; Pfizer/SFJ Pharmaceuticals)
    • Patritumab (AMG 888; Amgen/第一三共)
  • ALK陽性NSCLC
    • Alectinib (RO5424802/CH5424802; Roche)
  • ALK・EGFR変異陰性NSCLC
    • Selumetinib (AZD6244; Array/AstraZeneca)
    • Veliparib (ABT-888; AbbVie)
    • Gemzar (necitumumab; Eli Lilly)
    • Bavituximab (Peregrine)
    • Abemaciclib (LY2835219; Eli Lilly)
    • Ganetespib (STA-9090; Synta)

KOL

  • 北米のKOL
  • 欧州のKOL
目次
Product Code: 596200416

The rapidly evolving non-small cell lung cancer (NSCLC) treatment algorithm is becoming increasingly complex and fragmented. Every advancement brings a new set of questions and concerns. This comprehensive report presents all the facts as they stand today, plus expert insights on the likely state of affairs tomorrow.

Which therapies are most likely to make a significant difference in the NSCLC field? Will we learn to use them to their fullest potential and in the optimal sequence? Can we afford them?

Non-Small Cell Lung Cancer: KOL Insight provides a review of the marketplace and the pipeline with an emphasis on established and emerging treatment pathways. Interviews with 12 KOLs add future-facing perspective to the data. The result is an insider's guide to the intricacies of a critical and complex market.

Top Benefits

  • Understand how your product is perceived, or is likely to be perceived, by the marketplace
  • Learn about the strengths and weaknesses of your competitors
  • Consider new positioning approaches that will put your product in the most favorable light possible
  • Understand opportunities and threats in the marketplace
  • UGain the insights required to better direct your sales and/or marketing teams toward success

Critical Questions Answered

  • Which new drugs are likely to disrupt or reshape the treatment algorithm for NSCLC?
  • Which clinical trials have the greatest potential to impact the future treatment of NSCLC?
  • How is the use of current targeted and immune therapies evolving, or likely to evolve?
  • What are the experts' greatest concerns about new and future therapies?
  • How will biomarkers and patient segmentation affect the future of treatment of NSCLC?

Key Areas Covered

  • Currently used, and late-stage pipeline, targeted and immune therapies for NSCLC
  • Summaries and analyses of the most significant, ongoing late-stage clinical trials
  • Overviews of current treatment algorithms based on patient segment, line of therapy, and patient characteristics
  • Considerations of treatment cost versus efficacy

Current Treatments Covered

Immunotherapy

  • Opdivo (nivolumab; Bristol-Myers Squibb)

EGFR mutation-positive NSCLC

  • Tarceva (erlotinib; Astellas/Roche)
  • Iressa (gefitinib; AstraZeneca)
  • Gilotrif/Giotrif (afatinib; Boehringer Ingelheim)

ALK-positive NSCLC

  • Zykadia (ceritinib; Novartis)

ALK and EGFR mutation-negative NSCLC

  • Avastin (bevacizumab; Roche)
  • Vargatef (nintedanib; Boehringer Ingelheim)
  • Cyramza (ramucirumab; Eli Lilly)

Pipeline Therapies Covered

Immunotherapy

  • Keytruda (pembrolizumab; Merck & Co.)
  • Atezolizumab (MPDL3280A; Roche)
  • Durvalumab (MEDI4736; AstraZeneca)
  • Yervoy (ipilimumab; BMS)

EGFR mutation-positive NSCLC

  • Mereletinib (AZD9291; AstraZeneca)
  • Rociletinib (CO-1686; Celgene/Clovis Oncology)
  • Dacomitinib (PF-00299804; Pfizer/SFJ Pharmaceuticals)
  • Patritumab (AMG 888; Amgen/Daiichi Sankyo)

ALK-positive NSCLC

  • Alectinib (RO5424802/CH5424802; Roche)

ALK and EGFR mutation-negative NSCLC

  • Selumetinib (AZD6244; Array/AstraZeneca)
  • Veliparib (ABT-888; AbbVie)
  • Gemzar (necitumumab; Eli Lilly)
  • Bavituximab (Peregrine)
  • Abemaciclib (LY2835219; Eli Lilly)
  • Ganetespib (STA-9090; Synta)

Key Opinion Leaders

KOLs from North America:

  • Paul Bunn, Distinguished Professor, Division of Medical Oncology, University of Colorado Edward Garon, Associate Professor, Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Giuseppe Giaccone, Associate Director for Clinical Research, Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University, Washington, DC
  • Leora Horn, Assistant Professor of Medicine (Haematology/Oncology) and Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, Tennessee
  • Joan Shiller, Deputy Director of the Simmons Comprehensive Cancer Center and Division Director of Hematology/Oncology, University of Texas-Southwestern Medical Center, Texas
  • Mark Socinski, Professor of Medicine and Thoracic Surgery, University of Pittsburgh School of Medicine, Pennsylvania

KOLs from Europe:

  • Ahmed Awada, Professor and Head of the Medical Oncology Clinic, Jules Bordet Institute, Brussels & Free Universities, Brussels, Belgium
  • Federico Cappuzzo, Professor and Director of Medical Oncology, Ospedale Civile di Livorno, Istituto Toscano Tumori-Ospedale Civile, Livorno, Italy
  • Solange Peters, Head of Thoracic Malignancies Program, Department of Oncology, University of Lausanne, Switzerland
  • David Planchard, Associate Professor, Department of Medical Oncology (Thoracic Oncology Group), Gustave-Roussy, France
  • Nick Thatcher, previously held the post of Professor of Medical Oncology at the Christie Hospital NHS Trust in Manchester, England
  • Anonymous KOL, Germany
Back to Top